A cytokine named TRAIL binds to TRAIL receptors and kills cancer cells, but not normal cells.
Therefore, various anticancer drugs targeting TRAIL receptors have been developed and gained great attention as a promising cancer therapeutics, but a certain population of cancer patients does not respond to the therapy.
Therefore, many researchers have tried to identify a key molecule that determine the sensitivity of cancer cells to the TRAIL therapy.
The surface of every cell in our body is decorated with sugar chains called glycans, which determines a character of cells and enable cells to talk to each other.
Glycan structures on the cell surface dramatically change when cells become cancerous.
In this multi-institutional study led by associate professor Moriwaki in Toho University and professor Miyoshi in Osaka University identified the glycan structure that makes cancer cells vulnerable to the death-inducing cytokine, TRAIL, and paved the new way to develop a predictive biomarker for the TRAIL therapy.
Previously, Drs. Moriwaki and Miyoshi found that fucose, which is one of building blocks of glycans, is an important sugar affecting the sensitivity of cancer cells to TRAIL.
This time, they closely looked at the structures of glycans carrying fucose and discovered that cancer cells highly expressing the specific glycan structure named Lewis glycans on the surface were more vulnerable to TRAIL-induced cell death.
They also found that although Lewis glycans are attached to proteins and lipids on the surface, Lewis glycans on lipids, but not on proteins, enhance TRAIL sensitivity.
Furthermore, they could predict the sensitivity of colon cancer patient-derived cancer cells to TRAIL-induced cell death by testing the expression level of Lewis glycans.
Therefore, this specific glycan structure is expected to be a valuable biomarker to predict the effectiveness of the TRAIL therapy.
Dr. Tomoya Fukuoka, a lead author of the study, said ‘‘These findings shed light on the regulatory mechanism of TRAIL-induced cell death and encourage the development of a novel therapeutic strategy targeting the TRAIL signaling. Furthermore, TRAIL resistance is a vital intrinsic mechanism that renders cancer cells insensitive to certain kind of cancer immunotherapy, so these findings also have a great impact on the development of a predictive biomarker for cancer immunotherapy.’’
Source: Toho University
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.